Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2015

View Archived Issues

Cantargia licenses use of BioWa's Potelligent platform to produce CAN-04

Investigators develop and characterize a novel series of anticoronavirus agents

Immunocore and Lilly collaborate to study immunotherapies for melanoma

Actelion and Max Planck Society form new start-up Vaxxilon

Amarna Therapeutics partners with CBmed on development of immunotherapies

Taisho and Ablynx sign exclusive license agreement for ozoralizumab in Japan

Herantis Pharma granted European government loan for Parkinson's study

Safety board recommends phase III rindopepimut study continue

Scientists disclose phase I results for PepCan

Clinical endpoints met in phase II study of P2B-001 in early Parkinson's disease

MK-1439A enters two new phase III studies in HIV

Preclinical data of SIRM antibody support further development

KBP-089: an antiobesity dual amylin and calcitonin receptor agonist

AMAG to acquire Cord Blood Registry

Entasis debuts with a portfolio of drug candidates to treat drug-resistant infections

Teva and Xenon provide update on TV-45070 phase IIb study in osteoarthritis pain

GlaxoSmithKline presents phase Ib results of GSK-2256098

Panther Biotechnology to acquire Alchemia Oncology

Results from metformin arm of phase II trial of BI-187004

Sun Biomedical reports conditions met for acquisition of Dimerix

Allergan discloses S1P1 receptor modulators

Genentech presents ERK inhibitors

Ignyta's new clinical trial assay to support STARTRK program for entrectinib

Prolong's novel ANF compound for hematopoiesis deficiencies

Biogen and Sunesis patent BTK inhibitors

FDA extends review of cobimetinib NDA

Gilead submits NDA for emtricitabine/rilpivirine/tenofovir alafenamide in HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...